Abstract
Purpose: To assess the economic burden of non-infectious inflammatory eyedisease (NIIED) in a commercially-insured population in the United States Methods: Adult patients with a NIIED diagnosis between 2006 and 2015 were selected from a de-identified, privately insured claims database and were matched 1:1 to a non-NIIED control. Ophthalmologic complications, direct healthcare resource use and costs, and indirect work loss (from the payer perspective) were calculated for a 12-month period and compared across the 2 cohorts. Results: Among the 14 876 matched pairs, NIIED patients were significantly more likely than controls to experience ocular complications, including glaucoma and cataracts (p < 0.001). NIIED patients had significantly higher healthcare resource utilization and costs compared with matched controls (relative difference 40%, p < 0.001). NIIED patients missed 12.2 days of work ($2925 annual work-loss costs), 46% more than non-NIIED patients (p < 0.001). Conclusion: NIIED imposes a significant clinical and economic burden, suggesting an unmet need for expanded access to alternative treatment options.
| Original language | English (US) |
|---|---|
| Journal | Ocular Immunology and Inflammation |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- economic burden
- healthcare resource use
- indirect work loss
- non-infectious inflammatory eye disease
- opthalmologic complications
ASJC Scopus subject areas
- Immunology and Allergy
- Ophthalmology
Cite this
Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States. / Albini, Thomas A; Rice, J. Bradford; White, Alan G.; Johnson, Michaela; Reiff, Julie; Lima, Antonio Flavio; Bartels-Peculis, Laura; Ciepielewska, Gosia; Nelson, Winnie W.
In: Ocular Immunology and Inflammation, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
AU - Albini, Thomas A
AU - Rice, J. Bradford
AU - White, Alan G.
AU - Johnson, Michaela
AU - Reiff, Julie
AU - Lima, Antonio Flavio
AU - Bartels-Peculis, Laura
AU - Ciepielewska, Gosia
AU - Nelson, Winnie W.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Purpose: To assess the economic burden of non-infectious inflammatory eyedisease (NIIED) in a commercially-insured population in the United States Methods: Adult patients with a NIIED diagnosis between 2006 and 2015 were selected from a de-identified, privately insured claims database and were matched 1:1 to a non-NIIED control. Ophthalmologic complications, direct healthcare resource use and costs, and indirect work loss (from the payer perspective) were calculated for a 12-month period and compared across the 2 cohorts. Results: Among the 14 876 matched pairs, NIIED patients were significantly more likely than controls to experience ocular complications, including glaucoma and cataracts (p < 0.001). NIIED patients had significantly higher healthcare resource utilization and costs compared with matched controls (relative difference 40%, p < 0.001). NIIED patients missed 12.2 days of work ($2925 annual work-loss costs), 46% more than non-NIIED patients (p < 0.001). Conclusion: NIIED imposes a significant clinical and economic burden, suggesting an unmet need for expanded access to alternative treatment options.
AB - Purpose: To assess the economic burden of non-infectious inflammatory eyedisease (NIIED) in a commercially-insured population in the United States Methods: Adult patients with a NIIED diagnosis between 2006 and 2015 were selected from a de-identified, privately insured claims database and were matched 1:1 to a non-NIIED control. Ophthalmologic complications, direct healthcare resource use and costs, and indirect work loss (from the payer perspective) were calculated for a 12-month period and compared across the 2 cohorts. Results: Among the 14 876 matched pairs, NIIED patients were significantly more likely than controls to experience ocular complications, including glaucoma and cataracts (p < 0.001). NIIED patients had significantly higher healthcare resource utilization and costs compared with matched controls (relative difference 40%, p < 0.001). NIIED patients missed 12.2 days of work ($2925 annual work-loss costs), 46% more than non-NIIED patients (p < 0.001). Conclusion: NIIED imposes a significant clinical and economic burden, suggesting an unmet need for expanded access to alternative treatment options.
KW - economic burden
KW - healthcare resource use
KW - indirect work loss
KW - non-infectious inflammatory eye disease
KW - opthalmologic complications
UR - http://www.scopus.com/inward/record.url?scp=85062364098&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062364098&partnerID=8YFLogxK
U2 - 10.1080/09273948.2018.1560476
DO - 10.1080/09273948.2018.1560476
M3 - Article
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
SN - 0927-3948
ER -